[HTML][HTML] Apixaban: a clinical pharmacokinetic and pharmacodynamic review
W Byon, S Garonzik, RA Boyd, CE Frost - Clinical pharmacokinetics, 2019 - Springer
Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …
and has been approved for clinical use in several thromboembolic disorders, including …
[HTML][HTML] Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
W Byon, S Garonzik, RA Boyd… - Clinical …, 2019 - ncbi.nlm.nih.gov
Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …
and has been approved for clinical use in several thromboembolic disorders, including …
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
W Byon, S Garonzik, RA Boyd… - Clinical …, 2019 - search.proquest.com
Abstract Published online: 14 May 2019© The Author (s) 2019 Abstract Apixaban is an oral,
direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa, and has been …
direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa, and has been …
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
W Byon, S Garonzik, RA Boyd, CE Frost - Clinical Pharmacokinetics, 2019 - europepmc.org
Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …
and has been approved for clinical use in several thromboembolic disorders, including …
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
W Byon, S Garonzik, RA Boyd… - Clinical …, 2019 - pubmed.ncbi.nlm.nih.gov
Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …
and has been approved for clinical use in several thromboembolic disorders, including …
[引用][C] Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
W Byon, S Garonzik, RA Boyd, CE Frost - Clinical Pharmacokinetics, 2019 - cir.nii.ac.jp
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
W Byon, S Garonzik, RA Boyd, CE Frost - Clinical Pharmacokinetics, 2019 - europepmc.org
Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …
and has been approved for clinical use in several thromboembolic disorders, including …